Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients

Yu, Wenbin; Liu, Zimei; Tang, Lina; Lin, Feng; Yao, Yang; Shen, Zan

doi:10.1038/s41598-017-14521-7

Cited by 15 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For lung metastases, stereotactic RT, radiofrequency ablation or cryotherapy might be used as alternative options in patients unfit for surgery [IV, B]. Some groups also consider radiofrequency ablation [52,53] and stereotactic RT [54] to be potential alternative local treatment options for primary lung or bone metastases [52][53][54].…”

Section: Annals Of Oncologymentioning

confidence: 99%

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Casali

Bielack

Abecassis³

et al. 2018

Annals of Oncology

448

412

View full text Add to dashboard Cite

Section: Annals Of Oncologymentioning

confidence: 99%

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Casali

Bielack

Abecassis³

et al. 2018

Annals of Oncology

448

412

View full text Add to dashboard Cite

“…82,90 Limited success has been achieved using radiofrequency ablation and stereotactic radiotherapy as an alternative local treatment option for primary lung or bone metastases. 91,92 Osteosarcoma: Bone Metastasis…”

Section: Osteosarcoma: Lung Metastasismentioning

confidence: 99%

<p>Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects</p>

Pushpam¹,

Garg²,

Ganguly³

et al. 2020

OTT

View full text Add to dashboard Cite

Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/ refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need.

show abstract

“…21); (3) radiotherapy, including stereotactic radiosurgery, carbon-ion radiotherapy, etc. [ 21 , 22 ]; (4) genetic engineering, e.g., biological genetic engineering-edited miRNAs that target RNA molecules [ 23 ]; (5) stem cell therapy (Table 5 ; No. 13, 37); and (6) novel alternative therapeutic drugs originating from Chinese herbal extracts.…”

Section: Discussionmentioning

confidence: 99%

A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019

Tao

Meng

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background In recent decades, the 5-year survival rate of osteosarcoma remains poor, despite the variety of operations, and exploration of drug therapy has become the key to improvement. This study investigates the contribution of different aspects in osteosarcoma and cure, and predicts research hotspots to benefit future clinical outcomes. Methods The Web of Science and PubMed databases were queried to collect all relevant publications related to osteosarcoma and cure from 2009 to 2019. These data were imported into CiteSpace and the Online Analysis Platform of Literature Metrology for bibliometric analysis. Bi-clustering was performed on Bibliographic Item co-occurrence Matrix Builder (BICOMB) and gCLUTO to identify hotspots. Additionally, completed clinical trials on osteosarcoma with results past phase II were collated. Results A total of 2258 publications were identified in osteosarcoma and cure from 2009 to 2019. China has the largest number of publications (38.49%), followed by the United States (23.03%) with the greatest impact (centrality = 0.44). The centrality of most institutions is < 0.1, and Central South University and Texas MD Anderson Cancer Center possess the highest average citation rates of 3.25 and 2.87. BMC cancer has the highest average citation rate of 3.26 in 772 journals. Four authors (Picci P, Gorlick R, Bielack SS and Bacci G) made the best contributions. We also identified eight hotspots and collected 41 clinical trials related to drug research on osteosarcoma. Conclusions The urgent need exists to strengthen global academic exchanges. Overcoming multidrug resistance in osteosarcoma is the focus of past, present and future investigations. Transformation of the metastasis pattern, microenvironment genetics mechanism, alternative methods of systemic chemotherapy and exploration of traditional Chinese medicine is expected to contribute to a new upsurge of research.

show abstract

Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients

Cited by 15 publications

References 40 publications

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

<p>Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects</p>

A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019

Contact Info

Product

Resources

About